These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 971653)

  • 21. Withdrawal symptoms after long-term treatment with neuroleptics.
    Krystof J; Zyg J; Mitkiewicz S; Kaczyński J
    Pol Med J; 1972; 11(1):189-95. PubMed ID: 5040995
    [No Abstract]   [Full Text] [Related]  

  • 22. Treating prodromal episodes to prevent relapse in schizophrenia.
    Herz MI; Glazer W; Mirza M; Mostert M; Hafez H
    Br J Psychiatry Suppl; 1989 Jul; (5):123-7. PubMed ID: 2574984
    [No Abstract]   [Full Text] [Related]  

  • 23. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.
    Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC
    Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The most important side effects of clozapine (Leponex) and their treatment].
    Küchenhoff B
    Psychiatr Prax; 1993 Nov; 20(6):201-6. PubMed ID: 8310092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV; Brown WA; Laughren TP
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double blind controlled study of ECT vs chlorpromazine in schizophrenia.
    Bagadia VN; Abhyankar RR; Doshi J; Pradhan PV; Shah LP
    J Assoc Physicians India; 1983 Oct; 31(10):637-40. PubMed ID: 6671932
    [No Abstract]   [Full Text] [Related]  

  • 27. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Somatic disorders during long-term drug treatment of schizophrenic patients].
    vom Brocke I
    Internist (Berl); 1974 May; 15(5):268-70. PubMed ID: 4213663
    [No Abstract]   [Full Text] [Related]  

  • 29. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
    Pecknold JC
    J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Qualitative and quantitative report on chlorpromazine and metabolites in plasma, erythrocytes and erythrocyte washings from chronically medicated schizophrenic patients.
    Turano P; March JE; Turner WJ; Merlis S
    J Med; 1972; 3(2):109-20. PubMed ID: 4507068
    [No Abstract]   [Full Text] [Related]  

  • 31. Alpha methyldopa-chlorpromazine interaction in schizophrenic patients.
    Chouinard G; Pinard G; Prenoveau Y; Tetreault L
    Curr Ther Res Clin Exp; 1973 Feb; 15(2):60-72. PubMed ID: 4632508
    [No Abstract]   [Full Text] [Related]  

  • 32. DISSIPATION OF PHENOTHIAZINE EFFECT AND RECURRENCE OF SCHIZOPHRENIC PSYCHOSIS.
    LUTZ EG
    Dis Nerv Syst; 1965 Jun; 26():355-7. PubMed ID: 14315069
    [No Abstract]   [Full Text] [Related]  

  • 33. The negative symptoms of schizophrenia and the monoamine oxidase inhibitors.
    Bucci L
    Psychopharmacology (Berl); 1987; 91(1):104-8. PubMed ID: 3103152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication.
    Prien RF; Cole JO; Belkin NF
    Br J Psychiatry; 1969 Jun; 115(523):679-86. PubMed ID: 5806858
    [No Abstract]   [Full Text] [Related]  

  • 35. Estimation of drug rejection by schizophrenic in-patients, with analysis of clinical factors.
    Wilson JD; Enoch MD
    Br J Psychiatry; 1967 Feb; 113(495):209-11. PubMed ID: 6032481
    [No Abstract]   [Full Text] [Related]  

  • 36. Hypermnesia and schizophrenia.
    Steinberg HR
    Psychol Rep; 1969 Aug; 25(1):195-8. PubMed ID: 5366378
    [No Abstract]   [Full Text] [Related]  

  • 37. LONG TERM DRUG-INDUCED SYMPTOM MODIFICATION IN SCHIZOPHRENIC OUTPATIENTS.
    ENGELHARDT DM; FREEDMAN N; HANKOFF LD; MANN D; MARGOLIS R
    J Nerv Ment Dis; 1963 Sep; 137():231-41. PubMed ID: 14051937
    [No Abstract]   [Full Text] [Related]  

  • 38. Postimperative negative variation (PINV) in ambulatory schizophrenic patients.
    Chouinard G; Annable L; Dubrovsky B; Dongier M
    Compr Psychiatry; 1975; 16(5):457-60. PubMed ID: 1175378
    [No Abstract]   [Full Text] [Related]  

  • 39. Picture recognition as an index of social sensitivity in chronic schizophrenia: the effects of chlorpromazine.
    SAMPSON PH; RAY TS; PUGH LA; CLARK ML
    J Consult Psychol; 1962 Dec; 26():510-4. PubMed ID: 13976148
    [No Abstract]   [Full Text] [Related]  

  • 40. Lithium toxicity with phenothiazine withdrawal.
    Pakes GE
    Lancet; 1979 Sep; 2(8144):701. PubMed ID: 90797
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.